Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Foghorn Therapeutics ( (FHTX) ).
Adam M. Koppel, M.D., Ph.D., has resigned from the board of directors of Foghorn Therapeutics Inc. effective immediately, leaving his roles on the Audit Committee and Nominating and Corporate Governance Committee. His departure was not due to any disagreements with the company’s operations, policies, or practices, and his term was set to expire at the 2025 Annual Meeting.
More about Foghorn Therapeutics
YTD Price Performance: -25.27%
Average Trading Volume: 154,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $268M
For an in-depth examination of FHTX stock, go to TipRanks’ Stock Analysis page.
